Astellas and Optimer collaborate on fidaxomicin in Japan

Monday, April 2, 2012 03:57 PM

San Diego-based Optimer Pharmaceuticals and Tokyo-based Astellas Pharma have formed an exclusive collaboration and license agreement to develop and commercialize fidaxomicin tablets in Japan for the treatment of Clostridium difficile infection (CDI) affecting the colon.

In return for the exclusive license to fidaxomicin in Japan, Optimer is entitled to receive a one-time, up-front cash payment of $20 million from Astellas. Optimer is also eligible to receive up to an additional $70 million in milestone payments. Furthermore, Optimer is entitled to receive payments from Astellas that provide a return resulting in a double digit percent of Astellas net sales in the territory. Astellas is responsible for all future costs associated with the development and commercialization of fidaxomicin in Japan.

Yoshihiko Hatanaka, president and CEO of Astellas Pharma, said, "We believe that fidaxomicin's highly differentiated clinical profile, which has been confirmed by clinical studies conducted in the U.S. and E.U., has the potential to provide a new and unique treatment option for patients in Japan.”

"Astellas is a leader in the anti-infective market in Japan,” explained Optimer’s president and CEO, Pedro Lichtinger. “Leveraging their expertise efficiently helps realize the potential of fidaxomicin to meet the serious unmet needs of CDI patients in Japan, helping to address the risk of recurrence inherent in the disease, while optimizing the market opportunity for our shareholders.”

In 2011, Optimer entered into a commercial partnership with Astellas Pharma Europe to develop and market fidaxomicin under the trade name Dificlir in Europe and other countries in the Middle East, Africa and the Commonwealth of Independent States. The EMA granted marketing authorization to Dificlir in December 2011 and Astellas Pharma Europe expects to begin selling Dificlir in the first of its territories starting in 2012.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 25

Verizon Communications enters clinical trial space with technology, network, and cloud and data services

Sponsors look to the power of genomic profiling to screen, enroll patients in trials for targeted therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs